62.5% of Biologics Professionals Have Strategy in Place to Mitigate Risks of Contamination

Sept. 20, 2011 - PRLog -- Within the next five years, the global biologics market is set to exceed $239 billion (£145 billion) in value, according to recent research by Bharat Book. As innovation brings down production costs and more comprehensive pipelines emerge, there remains just one critical area that threatens to hold developers back. Mitigation of risks arising from the contamination of adventitious agents is still an area in which expertise is limited.

Since 2009, a number of high-profile cases involving big names such as GlaxoSmithKline (GSK) and Genzyme have alerted biologics producers to an urgent requirement for measures to avoid contamination. They also need to be equipped, should the worst happen, to minimise the negative impact of a contamination as efficiently as possible.

A recent Pharma IQ study, conducted ahead of an Ensuring Adventitious Agent Safety in Biologics event in October 2011, it was revealed that almost two-thirds of producers do indeed have strategies in place to mitigate the risks of contamination. Among the survey respondents were key decision makers from a range of different types of company.

To download this report in full please click here:
http://www.adventitiousagentsevent.com/Event.aspx?id=5532...